APIM-peptide targeting PCNA improves the efficacy of docetaxel treatment in the TRAMP mouse model of prostate cancer

Docetaxel is the chemotherapeutic choice for metastatic hormone-refractory prostate cancer, however, it only marginally improves the survival rate. The purpose of the present study was to examine if a peptide targeting the cellular scaffold protein PCNA could improve docetaxel’s efficacy. We found t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Søgaard, Caroline K., Moestue, Siver A., Rye, Morten B., Kim, Jana, Nepal, Anala, Liabakk, Nina-Beate, Bachke, Siri, Bathen, Tone F., Otterlei, Marit, Hill, Deborah K.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2018
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5837745/
https://ncbi.nlm.nih.gov/pubmed/29545934
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24357
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados